Daré Bioscience Announces Grant to Support Biotherapeutic Product Development
SAN DIEGO, Jan. 17, 2024 (GLOBE NEWSWIRE) — Daré Bioscience, Inc. (NASDAQ:DARE), a leader in women’s health innovation, today announced it has received a grant from the Bill & Melinda Gates Foundation (the foundation) of $750,000 to fund activities related to bacteria-based live biotherapeutic product development. Daré previously received a grant of approximately $585,000 from the foundation for development of a hydrogel formulation for delivery of live biotherapeutics to support vaginal health in November 2022.
Related news for (DARE)
- Stocks to Watch: Speculative Movers, Strategic Shifts, and a Big Bet on Live Entertainment
- Positive Ovaprene Interim Phase 3 Results Support Potential First-in-Class, Hormone-Free Monthly Contraceptive
- Today’s Top Performers: MoBot’s Market Review 07/11/25 08:00 AM
- Daré Bioscience Receives $6 Million Non-Dilutive Grant Installment; $37.8M to Date of up to $49M Commitment Supporting Smart Drug Delivery Device for Contraception; Platform has Broader Application Potential in Obesity and Metabolic Disorders
- 24/7 Market News Snapshot 11 July, 2025 – Dare Bioscience, Inc. Common Stock (NASDAQ:DARE)